| Patient | Gilda Radner |
|---|---|
| Date of birth | 1946-06-28 |
| Identifiers | MRN HR-ML026-SYN-TD; SSN (made up) 000-26-8821 |
| Document date | 1986-07-14 |
| Author | Delia Marchand, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Review at the midpoint of chemotherapy, on the day of cycle 4. [S]
Ms. Radner returns on the day of her fourth cycle of carboplatin and paclitaxel. Cycles 2 and 3 were given on schedule. The cold she had a week after cycle 2 cleared in five days without a fever. Nausea lasts a day or two after each cycle and is controlled with ondansetron, which she uses two or three times per cycle. For about two weeks she has had tingling in her toes and fingertips that does not stop her buttoning clothes, walking, or writing. Her hair has fallen out and she wears a scarf. Hot flashes continue. She goes to her support group every other week. She has had no thoughts of self-harm. [S]
| Element | Detail |
|---|---|
| Treatment | Cycle 4 of 6 today; cycles 2 and 3 on schedule |
| Nausea | One or two days after each cycle; ondansetron two or three times |
| Neuropathy | Tingling in the toes and fingertips for two weeks; no effect on function |
| Infection | Cold after cycle 2 resolved without fever |
| Mood | PHQ-9 4; support group every other week |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired for a few days after each cycle; no fever |
| Gastrointestinal | Positive | Nausea for one or two days after each cycle; no vomiting; bowels regular |
| Neurological | Positive | Tingling in the toes and fingertips; no weakness or falls |
| Integumentary | Positive | Hair loss |
| Endocrine | Positive | Hot flashes |
| Respiratory | Negative | Cough gone; no breathlessness |
| Psychiatric | Negative | Mood steady; no thoughts of self-harm |
7 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Enoxaparin 40 mg/0.4 mL prefilled syringe, 40 mg under the skin once daily for 28 days after surgery | 40 mg under the skin once daily for 28 days | Subcutaneous route | 1986-04-21 to 1986-05-18 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain after surgery, no more than 3 g a day | Two tablets every 6 hours as needed | Oral route | 1986-04-21 to 1986-05-05 | completed | S |
| Carboplatin 10 mg/mL injection, 610 mg (AUC 5) intravenously on day 1 of each 21-day cycle, for six cycles | Day 1 every 21 days for six cycles | Intravenous route | 1986-05-12 to 1986-08-25 | completed | S |
| Paclitaxel 6 mg/mL injection, 275 mg (175 mg/m2) intravenously over 3 hours on day 1 of each 21-day cycle, for six cycles, after dexamethasone, diphenhydramine and famotidine | Day 1 every 21 days for six cycles | Intravenous route | 1986-05-12 to 1986-08-25 | completed | S |
| Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea | One tablet every 8 hours as needed for nausea | Oral route | 1986-05-12 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1986-07-14 | Body height | 160 | cm | S |
| 1986-07-14 | Body weight | 55.9 | kg | S |
| 1986-07-14 | Body mass index (BMI) [Ratio] | 21.8 | kg/m2 | S |
| 1986-07-14 | Systolic blood pressure | 110 | mm[Hg] | S |
| 1986-07-14 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 1986-07-14 | Heart rate | 80 | /min | S |
| 1986-07-14 | Respiratory rate | 14 | /min | S |
| 1986-07-14 | Body temperature | 36.6 | Cel | S |
| 1986-07-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1986-07-14 | Hemoglobin [Mass/volume] in Blood | 10.3 | g/dL | 11.6-15 g/dL | Low | S |
| 1986-07-14 | Leukocytes [#/volume] in Blood by Automated count | 4.1 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1986-07-14 | Neutrophils [#/volume] in Blood by Automated count | 1.9 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 1986-07-14 | Platelets [#/volume] in Blood by Automated count | 188 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1986-07-14 | Creatinine [Mass/volume] in Serum or Plasma | 0.7 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1986-07-14 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1981)/1.73 sq M | 113 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1986-07-14 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 7-35 U/L | Normal | S |
| 1986-07-14 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.4 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1986-07-14 | Magnesium [Mass/volume] in Serum or Plasma | 1.7 | mg/dL | 1.7-2.2 mg/dL | Normal | S |
| 1986-07-14 | Cancer Ag 125 [Units/volume] in Serum or Plasma | 21 | U/mL | <=35 U/mL | Normal | S |
| 1986-07-14 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S |
Vital signs recorded on 1986-07-14; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 55.9 kg; blood pressure 110/70, pulse 80 |
| Abdomen | Soft, non-tender; no fluid or mass |
| Neurological | Pinprick slightly reduced over the toes; vibration sense and ankle reflexes present; strength normal; steady gait |
| Skin | Alopecia; no rash |
| Psychiatric | Bright, engaged; organized |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Persistent bloating with tightness of her clothes, feeling full after a few bites, a dull lower abdominal and pelvic ache, and passing urine more often, on most days for about four weeks, in a woman of 39: the ovarian cancer symptom index is positive. Examination: a distended abdomen with shifting dullness and a firm, fixed, irregular mass in the right adnexa. Suspected ovarian cancer; transvaginal ultrasound, CT, CA-125 and gynecologic oncology review booked within the week | resolved | confirmed | R19.00 | S — Synthetic presenting problem linked to her documented abdominal symptoms; superseded by the diagnosis at the gynecologic oncology consultation. |
| High-grade serous carcinoma of both ovaries (Mullerian origin), diagnosed by image-guided omental core biopsy (PAX8 and WT1 positive, p53 aberrant), with bilateral adnexal masses, ascites, omental and diaphragmatic disease on CT: clinical FIGO stage IIIC; synthetic modern detail linked to her documented ovarian cancer | active | confirmed | C56.3 | S — Synthetic histology and stage; the documented diagnosis was stage IV ovarian cancer (D). |
| Peritoneal and omental metastases of the ovarian cancer, with ascites | active | confirmed | C78.6 | S — Synthetic extent of disease on CT and biopsy. |
| Family history of ovarian cancer in three relatives (her grandmother, an aunt, and a cousin) in a woman of Ashkenazi Jewish ancestry; no genetic testing in the family is known | active | confirmed | Z80.41 | S — Synthetic coding of her documented family history; the basis for genetic counseling. |
| Acute viral upper respiratory infection on day 8 of the second chemotherapy cycle: two days of sore throat, runny nose and a dry cough, without fever; rapid influenza and COVID-19 tests negative; resolved | resolved | confirmed | J06.9 | S — Synthetic acute infection; not a historical claim. |
| Symptomatic surgical menopause after bilateral salpingo-oophorectomy at 39: hot flashes and night sweats | active | confirmed | E89.41 | S — Synthetic consequence of the synthetic operation. |
| Chemotherapy-induced peripheral neuropathy from paclitaxel: tingling in the toes and fingertips, grade 1 (sensory only, no effect on daily activities) | active | confirmed | G62.0 | S — Synthetic common effect of paclitaxel. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count with neutrophils and platelets | Before each chemotherapy cycle | Completed today | Hemoglobin 10.3 g/dL, white cells 4.1, neutrophils 1.9, platelets 188; cycle 4 can be given. Cycles 2 and 3 were given on schedule in the infusion center |
| Laboratory | Creatinine and estimated kidney function (carboplatin dose) | Before each cycle | Completed today | Creatinine 0.70 mg/dL, eGFR 113; carboplatin dose unchanged |
| Laboratory | Liver tests (paclitaxel) | Before each cycle | Completed today | ALT 24 U/L, bilirubin 0.4 mg/dL |
| Laboratory | Magnesium | Before each cycle | Completed today | 1.7 mg/dL, at the lower limit; dietary advice and a check before each remaining cycle |
| Laboratory | CA-125 | At diagnosis; before each cycle when raised at diagnosis; at the end of treatment; then at each surveillance visit | Deferred | 21 U/mL today, now normal. A deviation: CA-125 was not drawn before cycles 2 and 3, which were given in the infusion center with blood counts only. No harm resulted: today's value shows a response, and imaging is planned at the end of treatment. Corrective action: CA-125 at the end of treatment and at every surveillance visit; no earlier values are recorded |
| Imaging | Response imaging | At the end of primary treatment, or sooner for symptoms or a rising CA-125 | Not indicated | Not needed at the midpoint: CA-125 normal and no symptoms; CT after cycle 6 |
| Examination | Peripheral neuropathy: symptoms and examination | At baseline and before each taxane cycle | Completed today | Grade 1 sensory neuropathy; full dose continues |
| Medication safety | Nausea and vomiting control | Each cycle | Completed today | Controlled: nausea one or two days per cycle, no vomiting |
| Medication safety | Paclitaxel infusion reaction prevention | Each paclitaxel dose | Completed today | No reaction in three cycles; same premedication |
| Survey | Distress and depression screen (PHQ-9) | At diagnosis, at each treatment phase, and when symptoms change | Completed today | PHQ-9 4 |
| Self-management | Menopausal symptoms after oophorectomy | Each visit after surgery | Completed today | Hot flashes continue; managed without medicine |
| Self-management | Infection precautions and fever plan | Each cycle | Completed today | Checks her temperature after each cycle; knows to call at once for 38.0 °C or more |
| Self-management | Psychosocial support and information | At diagnosis and throughout | Completed today | Support group every other week |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 4.2026 (2026); Salani R, et al. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol 2017;146(1):3-10 (2017); Hesketh PJ, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol 2020;38(24):2782-2797 (2020); Loprinzi CL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325-3348 (2020); Depression and Suicide Risk in Adults: Screening (2023); NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections (2026)
Follow-up: Cycles 5 and 6 every 21 days. CT about two weeks after cycle 6, then a review with the result and the maintenance decision. Next scheduled visit 1986-09-15: end of chemotherapy: CT and CA-125 response, and the start of olaparib maintenance. [S]